Metabolon’s diagnostic division is committed to creating a suite of metabolomics-driven clinical laboratory tests that may provide physicians with actionable information that aids in patient management. We do this by harnessing the power of metabolomics to discover novel biomarkers and translate them into useful clinical laboratory tests.
We currently offer three clinical diagnostics tests:
- Quantose IR™ is Metabolon’s first commercially available laboratory test in the obesity-related chronic disease space. It assesses the level of insulin resistance and monitors therapeutic improvement in a given prediabetic patient, to allow for intervention that could help delay or possibly prevent the onset of type 2 diabetes. Click here to learn more about Quantose.
- Prostarix™ and Prostarix™ Plus are Metabolon’s first commercially available laboratory tests in oncology. These tests are used to help physicans determine whether or not to proceed to prostate biopsy in patients with elevated levels of PSA (prostate specific antigen). Click here to learn more about Prostarix and Prostarix Plus.
These tests are currently available as Laboratory Developed Tests run in Metabolon’s Clinical Laboratory Improvement Amendments (CLIA)-certified and College of American Pathologists (CAP)-accredited clinical laboratory.
Moving forward, Metabolon is focused on developing and delivering other new diagnostic and prognostic tools with a specific focus on obesity-related chronic diseases (type 2 diabetes, cardiovascular disease, liver disease, and chronic kidney disease) and uro-oncology (cancers affecting the prostate, bladder and kidneys). We are currently pursuing the development of laboratory tests in the following areas:
- Liver disease
- Kidney function
- Prostate cancer
- Bladder cancer
- Tolerance to chemotherapy drugs (such as cisplatin)
We believe that our pipeline diagnostic products could eventually become important tools for the early detection of obesity-related chronic diseases and provide information that may help doctors better manage the care of their cancer patients.
All of our clinical diagnostics tests and pipeline products are developed using Metabolon’s proprietary metabolomics technology. Our global metabolomics screening technology, the DiscoveryHD4™ platform, enables the rapid discovery of clinically relevant metabolite biomarkers and their efficient translation into clinical practice. We believe that this technology holds the potential to accelerate the discovery and development of novel laboratory tests, and that these tests may improve/advance the management of some major human diseases.